Gérontopôle de Toulouse, Département de Médecine Interne et Gérontologie Clinique, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
J Nutr Health Aging. 2013 Feb;17(2):137-41. doi: 10.1007/s12603-012-0403-7.
The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom, the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) in Germany and the Haute Autorité de Santé (HAS) in France have recently set out guidelines on prescription of anti-dementia medication. The HAS proposes in particular that continuation of these drugs for longer than one year should be decided in multidisciplinary team meetings (MDTM).
To assess the feasibility of MDTM and the satisfaction of coordinating physicians from institutions for the dependent elderly (nursing home, NH) and expert physicians from memory clinics who have participated in the meetings.
Survey carried out among physicians who had participated in the MDTM held as part of the IDEM study (Interest of systematic tracking of dementia cases in NH: analysing the contribution of MDTM in Alzheimer's disease and related diseases; PHRC National 2009, Code 0910701). The survey evaluated the organization of MDTM and the physicians' opinion of these meetings.
The cases of 574 patients were discussed in MDTM involving 133 healthcare professionals (32 coordinating physicians, 48 expert physicians, 4 general practitioners and 49 other health professionals). The mean number of participants was 4.2±1.6. About 16 minutes were spent discussing the case of each resident. About 90% of physicians considered that the meetings were useful. Overall assessment of their efficacy was 11.5/20 for the coordinating physicians and 14.1/20 for the expert physicians. The benefits of MDTM in relation to the work entailed were considered important by 60% of expert physicians and 33% of coordinating physicians.
Our survey confirmed the feasibility of MDTM in the field of Alzheimer's disease. The overall benefit/workload ratio of the meetings was considered to be favorable for the expert physicians. The benefits of MDTM were turned out to be less appreciated by the coordinating physicians according to high workload involved.
英国的国家卫生与临床优化研究所（NICE）、德国的联邦联合委员会（IQWIG）和法国的高级卫生署（HAS）最近发布了关于抗痴呆药物处方的指南。HAS 特别提出，这些药物的续用应在多学科团队会议（MDTM）上做出决定。
评估 MDTM 的可行性以及参与会议的来自老年依赖机构（养老院，NH）的协调医生和来自记忆诊所的专家医生的满意度。
对参与 IDEM 研究（NH 中痴呆病例系统跟踪的意义：分析 MDTM 在阿尔茨海默病和相关疾病中的作用；PHRC 全国 2009 年，编号 0910701）中 MDTM 的医生进行调查。该调查评估了 MDTM 的组织以及医生对这些会议的看法。
共讨论了 574 例患者的 MDTM，涉及 133 名医疗保健专业人员（32 名协调医生、48 名专家医生、4 名全科医生和 49 名其他卫生专业人员）。每位居民的平均讨论参与者为 4.2±1.6 名。大约 16 分钟用于讨论每位居民的病例。大约 90%的医生认为会议有用。协调医生对其疗效的总体评估得分为 11.5/20，专家医生得分为 14.1/20。60%的专家医生和 33%的协调医生认为 MDTM 的益处与其带来的工作负担相关，认为这是重要的。
我们的调查证实了 MDTM 在阿尔茨海默病领域的可行性。会议的总体效益/工作负荷比被认为对专家医生有利。根据所涉及的高工作量，协调医生对 MDTM 的益处评价较低。
